Table 1.
Demographics and Baseline Characteristics.a
| FOLFOX-HAIC group (n = 55) | Sorafenib group (n = 59) | P | |
|---|---|---|---|
| Age | .19 | ||
| ≤50 | 30 | 25 | |
| >50 | 25 | 34 | |
| Sex | .48 | ||
| Male | 50 | 56 | |
| Female | 5 | 3 | |
| ECOG performance status | .20 | ||
| 0 | 16 | 24 | |
| 1 | 39 | 35 | |
| HBV infection | .51 | ||
| Yes | 44 | 50 | |
| No | 11 | 9 | |
| Maximum tumor diameter, cm | .19 | ||
| ≤10 | 23 | 32 | |
| >10 | 32 | 27 | |
| Tumor number | .98 | ||
| Single | 12 | 13 | |
| Multiple | 43 | 46 | |
| Portal vein tumor thrombus | .65 | ||
| Absence | 37 | 42 | |
| Presence | 18 | 17 | |
| BCLC stage | .51 | ||
| B | 35 | 41 | |
| C | 20 | 18 | |
| AFP, ng/mL | .93 | ||
| ≤1000 | 21 | 23 | |
| >1000 | 34 | 36 | |
| Child-Pugh score | .67 | ||
| 5 | 48 | 53 | |
| 6 | 7 | 6 | |
| mALBI grade | .52 | ||
| 1 | 32 | 34 | |
| 2a | 15 | 20 | |
| 2b | 8 | 5 | |
| Therapy after progression | |||
| Sorafenib | 7 | 0 | .005 |
| FOLFOX-HAIC | 0 | 3 | .24 |
| Lenvatinib | 6 | 7 | .87 |
| Regorafenib | 0 | 8 | .006 |
| PD-1 inhibitor treatment | 1 | 5 | .21 |
| Radiotherapy | 3 | 2 | .67 |
Abbreviations: FOLFOX-HAIC group, hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin group; Sorafenib group, Sorafenib monotherapy group; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; BCLC, Barcelona Clinic Liver Cancer staging; AFP, alpha-fetoprotein; mALBI grade, modified albumin-bilirubin grade.
a
Data are expressed as n. P value was calculated by Student t tests or χ2 tests.